| Trait Information | |
| Identifier | MONDO_0000605 |
| Description | An immune system disease that has basis in dysregulation of the hypersensitivity reaction, an inflammatory response to an exogenous environmental antigen or an endogenous antigen initiated by the adaptive immune system. [ISBN-13: 978-0-7817-3514-8] | Trait category |
Other trait
|
| Synonyms |
6 synonyms
|
| Child trait(s) | 7 child traits |
| Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
|---|---|---|---|---|---|---|
| PGS000196 (G-PROB_SLE) |
PGP000081 | Knevel R et al. Sci Transl Med (2020) |
Systemic lupus erythematosus | systemic lupus erythematosus | 55 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000196/ScoringFiles/PGS000196.txt.gz |
| PGS000328 (GRS_SLE) |
PGP000099 | Reid S et al. Ann Rheum Dis (2019) |
Systemic lupus erythematosus | systemic lupus erythematosus | 57 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000328/ScoringFiles/PGS000328.txt.gz |
| PGS000754 (PRS_SLE) |
PGP000160 | Wang YF et al. Nat Commun (2021) |
Systemic lupus erythematosus | systemic lupus erythematosus | 293,684 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000754/ScoringFiles/PGS000754.txt.gz |
| PGS000771 (GRS95_SLEmain) |
PGP000178 | Chen L et al. Hum Mol Genet (2020) |
Systemic lupus erythematosus | systemic lupus erythematosus | 95 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000771/ScoringFiles/PGS000771.txt.gz | |
| PGS000772 (GRS95_SLEgen) |
PGP000178 | Chen L et al. Hum Mol Genet (2020) |
Systemic lupus erythematosus | systemic lupus erythematosus | 95 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000772/ScoringFiles/PGS000772.txt.gz | |
| PGS000780 (PRS135_allergy) |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Allergic disease | allergic disease | 135 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000780/ScoringFiles/PGS000780.txt.gz |
| PGS000800 (GRSw_SHARE) |
PGP000189 | Dijk FN et al. J Allergy Clin Immunol (2019) |
Allergic disease | allergic disease | 133 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000800/ScoringFiles/PGS000800.txt.gz |
| PGS000803 (wGRS41_SLE) |
PGP000192 | Kawai VK et al. Lupus (2021) |
Systemic lupus erythematosus | systemic lupus erythematosus | 41 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000803/ScoringFiles/PGS000803.txt.gz |
| PGS000810 (wGRS136_Allergy) |
PGP000195 | Ferreira MA et al. Nat Genet (2017) |
Allergic disease (asthma, hay fever or eczema) | allergic disease | 136 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000810/ScoringFiles/PGS000810.txt.gz |
| PGS000867 (GRS10_Allergy) |
PGP000213 | Arabkhazaeli A et al. Pediatr Allergy Immunol (2017) |
Allergy | allergic disease | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000867/ScoringFiles/PGS000867.txt.gz |
| PGS001109 (GBE_HC1021) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Vasomotor and allergic rhinitis (time-to-event) | vasomotor rhinitis, allergic rhinitis |
1,910 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001109/ScoringFiles/PGS001109.txt.gz |
| PGS001259 (GBE_HC49) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Hayfever/allergic rhinitis | seasonal allergic rhinitis | 349 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001259/ScoringFiles/PGS001259.txt.gz |
| PGS001283 (GBE_INI3761) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Allergic disease (hay fever, rhinitis or eczema) | allergic disease | 993 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001283/ScoringFiles/PGS001283.txt.gz |
| PGS001284 (GBE_BIN_FC10006152) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Allergic disease (hay fever, allergic rhinitis, or eczema) | allergic disease | 6,755 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001284/ScoringFiles/PGS001284.txt.gz |
| PGS001285 (GBE_BIN_FC5006152) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Allergic disease (hay fever, rhinitis, or eczema) (diagnosed by doctor) | allergic disease | 7,313 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001285/ScoringFiles/PGS001285.txt.gz |
| PGS001286 (GBE_BIN22126) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Allergic disease (hay fever or allergic rhinitis) (diagnosed by doctor) | allergic disease | 466 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001286/ScoringFiles/PGS001286.txt.gz |
| PGS001372 (GBE_INI22146) |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Age hayfever or allergic rhinitis diagnosed by doctor | allergic disease | 255 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001372/ScoringFiles/PGS001372.txt.gz |
| PGS001773 (PRS_atopicDermatitis) |
PGP000253 | Simard M et al. J Allergy Clin Immunol (2020) |
Moderate-to-severe atopic dermatitis | atopic eczema | 25 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001773/ScoringFiles/PGS001773.txt.gz |
| PGS001885 (portability-PLR_960.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Allergy/adverse effect of penicillin | drug allergy | 95 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS001885/ScoringFiles/PGS001885.txt.gz |
| PGS002097 (portability-ldpred2_960.2) |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Allergy/adverse effect of penicillin | drug allergy | 742,904 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002097/ScoringFiles/PGS002097.txt.gz |
| PGS002755 (Atopic_dermatitis_prscs) |
PGP000364 | Mars N et al. Am J Hum Genet (2022) |
Atopic dermatitis | atopic eczema | 1,090,702 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS002755/ScoringFiles/PGS002755.txt.gz |
| PGS003458 (PRS_AT) |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
General atopic disease | allergic disease | 124 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003458/ScoringFiles/PGS003458.txt.gz |
| PGS003459 (PRS_CO) |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
Atopic eczema or atopic disease | atopic eczema, allergic disease |
170 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003459/ScoringFiles/PGS003459.txt.gz |
| PGS003486 (PRS_AE) |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
Atopic eczema | atopic eczema | 71 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003486/ScoringFiles/PGS003486.txt.gz |
| PGS003487 (PRS_IL4) |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
General atopic disease (IL-4 related variants) | allergic disease | 25 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003487/ScoringFiles/PGS003487.txt.gz |
| PGS003488 (PRS_IL12) |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
General atopic disease (IL-12 related variants) | allergic disease | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003488/ScoringFiles/PGS003488.txt.gz |
| PGS003489 (PRS_IL17) |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
General atopic disease (IL-17 related variants) | allergic disease | 18 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003489/ScoringFiles/PGS003489.txt.gz |
| PGS003755 (wGRS_SLE) |
PGP000475 | Kwon YC et al. Arthritis Rheumatol (2023) |
Systemic lupus erythematosus | systemic lupus erythematosus | 122 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003755/ScoringFiles/PGS003755.txt.gz |
| PGS003756 (wGRS_SLE_non-HLA) |
PGP000475 | Kwon YC et al. Arthritis Rheumatol (2023) |
Systemic lupus erythematosus | systemic lupus erythematosus | 112 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003756/ScoringFiles/PGS003756.txt.gz |
| PGS003757 (wGRS_SLE_HLA) |
PGP000475 | Kwon YC et al. Arthritis Rheumatol (2023) |
Systemic lupus erythematosus | systemic lupus erythematosus | 10 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003757/ScoringFiles/PGS003757.txt.gz |
| PGS003960 (GRS57_SLE) |
PGP000509 | Barnado A et al. Arthritis Rheumatol (2023) |
Systemic lupus erythematosus | systemic lupus erythematosus | 57 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003960/ScoringFiles/PGS003960.txt.gz |
| PGS004587 (PRS23_AD) |
PGP000566 | Gu X et al. Ecotoxicol Environ Saf (2023) |
Atopic dermatitis | atopic eczema | 23 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004587/ScoringFiles/PGS004587.txt.gz |
| PGS004903 (PRS_ALL) |
PGP000633 | Al-Janabi A et al. J Allergy Clin Immunol (2023) |
Atopic dermatitis | atopic eczema | 38 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004903/ScoringFiles/PGS004903.txt.gz |
| PGS004917 (wGRS) |
PGP000648 | Cui J et al. Arthritis Rheumatol (2020) |
Systemic lupus erythematosus | systemic lupus erythematosus | 97 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS004917/ScoringFiles/PGS004917.txt.gz |
| PGS019275 (TPMI_476_Lassosum2) |
PGP000835 | Chen HH et al. Nature (2025) |
Allergic rhinitis | allergic rhinitis | 243,320 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019275/ScoringFiles/PGS019275.txt.gz | |
| PGS019276 (TPMI_476_LDpred2) |
PGP000835 | Chen HH et al. Nature (2025) |
Allergic rhinitis | allergic rhinitis | 939,881 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019276/ScoringFiles/PGS019276.txt.gz | |
| PGS019277 (TPMI_476_MegaPRS) |
PGP000835 | Chen HH et al. Nature (2025) |
Allergic rhinitis | allergic rhinitis | 17,340 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019277/ScoringFiles/PGS019277.txt.gz | |
| PGS019278 (TPMI_476_PRS-CS) |
PGP000835 | Chen HH et al. Nature (2025) |
Allergic rhinitis | allergic rhinitis | 983,820 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019278/ScoringFiles/PGS019278.txt.gz | |
| PGS019279 (TPMI_476_SBayesR) |
PGP000835 | Chen HH et al. Nature (2025) |
Allergic rhinitis | allergic rhinitis | 950,545 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019279/ScoringFiles/PGS019279.txt.gz | |
| PGS019593 (TPMI_695.4_Lassosum2) |
PGP000835 | Chen HH et al. Nature (2025) |
Lupus localized and systemic | systemic lupus erythematosus | 4,048 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019593/ScoringFiles/PGS019593.txt.gz | |
| PGS019594 (TPMI_695.4_LDpred2) |
PGP000835 | Chen HH et al. Nature (2025) |
Lupus localized and systemic | systemic lupus erythematosus | 939,805 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019594/ScoringFiles/PGS019594.txt.gz | |
| PGS019595 (TPMI_695.4_MegaPRS) |
PGP000835 | Chen HH et al. Nature (2025) |
Lupus localized and systemic | systemic lupus erythematosus | 351,328 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019595/ScoringFiles/PGS019595.txt.gz | |
| PGS019596 (TPMI_695.4_PRS-CS) |
PGP000835 | Chen HH et al. Nature (2025) |
Lupus localized and systemic | systemic lupus erythematosus | 983,762 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019596/ScoringFiles/PGS019596.txt.gz | |
| PGS019597 (TPMI_695.4_PRSmix+) |
PGP000835 | Chen HH et al. Nature (2025) |
Lupus localized and systemic | systemic lupus erythematosus | 1,071,408 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019597/ScoringFiles/PGS019597.txt.gz | |
| PGS019598 (TPMI_695.4_SBayesR) |
PGP000835 | Chen HH et al. Nature (2025) |
Lupus localized and systemic | systemic lupus erythematosus | 93,337 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019598/ScoringFiles/PGS019598.txt.gz | |
| PGS019599 (TPMI_695.42_Lassosum2) |
PGP000835 | Chen HH et al. Nature (2025) |
Systemic lupus erythematosus | systemic lupus erythematosus | 3,935 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019599/ScoringFiles/PGS019599.txt.gz | |
| PGS019600 (TPMI_695.42_LDpred2) |
PGP000835 | Chen HH et al. Nature (2025) |
Systemic lupus erythematosus | systemic lupus erythematosus | 939,805 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019600/ScoringFiles/PGS019600.txt.gz | |
| PGS019601 (TPMI_695.42_MegaPRS) |
PGP000835 | Chen HH et al. Nature (2025) |
Systemic lupus erythematosus | systemic lupus erythematosus | 366,324 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019601/ScoringFiles/PGS019601.txt.gz | |
| PGS019602 (TPMI_695.42_PRS-CS) |
PGP000835 | Chen HH et al. Nature (2025) |
Systemic lupus erythematosus | systemic lupus erythematosus | 983,763 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019602/ScoringFiles/PGS019602.txt.gz | |
| PGS019603 (TPMI_695.42_PRSmix+) |
PGP000835 | Chen HH et al. Nature (2025) |
Systemic lupus erythematosus | systemic lupus erythematosus | 1,071,406 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019603/ScoringFiles/PGS019603.txt.gz | |
| PGS019604 (TPMI_695.42_SBayesR) |
PGP000835 | Chen HH et al. Nature (2025) |
Systemic lupus erythematosus | systemic lupus erythematosus | 93,987 | https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS019604/ScoringFiles/PGS019604.txt.gz |
|
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|---|
| PPM000579 | PGS000196 (G-PROB_SLE) |
PSS000319| European Ancestry| 243 individuals |
PGP000081 | Knevel R et al. Sci Transl Med (2020) |
Reported Trait: Systemic lupus erythematosus diagnosis in patient with arthritis | — | AUROC: 0.61 [0.27, 0.86] | — | — | (Setting III: Selecting patients presenting with inflammatory arthritis at their first visit) |
| PPM000573 | PGS000196 (G-PROB_SLE) |
PSS000318| European Ancestry| 245 individuals |
PGP000081 | Knevel R et al. Sci Transl Med (2020) |
Reported Trait: Systemic lupus erythematosus diagnosis in patient with arthritis | — | AUROC: 0.79 [0.72, 0.85] | — | — | (Setting II: Assigning patient diagnoses based on medical records) |
| PPM000567 | PGS000196 (G-PROB_SLE) |
PSS000324| Multi-ancestry (including European)| 1,211 individuals |
PGP000081 | Knevel R et al. Sci Transl Med (2020) |
Reported Trait: Systemic lupus erythematosus diagnosis in patient with arthritis | — | AUROC: 0.74 [0.7, 0.78] | — | — | (Setting I: Assigning patient diagnoses based on billing codes) |
| PPM000882 | PGS000328 (GRS_SLE) |
PSS000438| European Ancestry| 15,383 individuals |
PGP000099 | Reid S et al. Ann Rheum Dis (2019) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.71 | Odds Ratio (OR; highest vs. lowest quartile): 7.48 [6.73, 8.32] | — | — |
| PPM000880 | PGS000328 (GRS_SLE) |
PSS000436| European Ancestry| 3,803 individuals |
PGP000099 | Reid S et al. Ann Rheum Dis (2019) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.78 | Odds Ratio (OR; highest vs. lowest quartile): 12.32 [9.53, 15.71] | — | — |
| PPM000883 | PGS000328 (GRS_SLE) |
PSS000436| European Ancestry| 3,803 individuals |
PGP000099 | Reid S et al. Ann Rheum Dis (2019) |
Reported Trait: Systemic Lupus damage score (SDI) | OR: 1.13 [1.03, 1.24] | — | Odds Ratio (OR; highest vs. lowest quartile): 1.47 [1.06, 2.04] | — | — |
| PPM000881 | PGS000328 (GRS_SLE) |
PSS000437| European Ancestry| 1,001 individuals |
PGP000099 | Reid S et al. Ann Rheum Dis (2019) |
Reported Trait: Systemic lupus erythematosus (onset before age 20) | — | AUROC: 0.83 | — | — | — |
| PPM000885 | PGS000328 (GRS_SLE) |
PSS000437| European Ancestry| 1,001 individuals |
PGP000099 | Reid S et al. Ann Rheum Dis (2019) |
Reported Trait: Nephritis in systemic lupus erythematosus patients | — | — | Hazard Ratio (HR; highest vs. lowest quartile): 2.53 [1.72, 3.71] | — | — |
| PPM000884 | PGS000328 (GRS_SLE) |
PSS000436| European Ancestry| 3,803 individuals |
PGP000099 | Reid S et al. Ann Rheum Dis (2019) |
Reported Trait: Systemic lupus erythematosus (age-at-onset) | — | — | Hazard Ratio (HR; highest vs. lowest quartile): 1.47 [1.22, 1.75] | — | — |
| PPM001919 | PGS000754 (PRS_SLE) |
PSS000963| East Asian Ancestry| 2,589 individuals |
PGP000160 | Wang YF et al. Nat Commun (2021) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.76 [0.74, 0.78] | — | — | — |
| PPM001920 | PGS000754 (PRS_SLE) |
PSS000960| European Ancestry| 1,340 individuals |
PGP000160 | Wang YF et al. Nat Commun (2021) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.65 | — | — | — |
| PPM001921 | PGS000754 (PRS_SLE) |
PSS000961| European Ancestry| 7,733 individuals |
PGP000160 | Wang YF et al. Nat Commun (2021) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.65 | — | — | — |
| PPM001922 | PGS000754 (PRS_SLE) |
PSS000962| European Ancestry| 1,112 individuals |
PGP000160 | Wang YF et al. Nat Commun (2021) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.62 | — | — | — |
| PPM002076 | PGS000754 (PRS_SLE) |
PSS001027| Additional Asian Ancestries| 3,996 individuals |
PGP000188 | Tangtanatakul P et al. Arthritis Res Ther (2020) |Ext. |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.76 | — | — | — |
| PPM001996 | PGS000771 (GRS95_SLEmain) |
PSS000994| European Ancestry| 524 individuals |
PGP000178 | Chen L et al. Hum Mol Genet (2020) |
Reported Trait: Renal disease age of onset | — | AUROC: 0.576 [0.518, 0.634] | — | — | Renal disease is used as a proxy for systemic lupus erythematosus severity |
| PPM001998 | PGS000771 (GRS95_SLEmain) |
PSS000994| European Ancestry| 524 individuals |
PGP000178 | Chen L et al. Hum Mol Genet (2020) |
Reported Trait: Renal disease age of onset | — | — | Odds Ratio (OR, top 20% vs bottom 20%): 3.155 [1.623, 6.133] | — | Renal disease is used as a proxy for systemic lupus erythematosus severity |
| PPM001997 | PGS000772 (GRS95_SLEgen) |
PSS000993| European Ancestry| 3,101 individuals |
PGP000178 | Chen L et al. Hum Mol Genet (2020) |
Reported Trait: Renal disease | — | — | Odds Ratio (OR, top 20% vs bottom 20%): 1.578 [1.25, 1.991] | — | Renal disease is used as a proxy for systemic lupus erythematosus severity |
| PPM002024 | PGS000780 (PRS135_allergy) |
PSS001008| Ancestry Not Reported| 897 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Atopic March | — | — | Relative Risk Ratio (RRR): 1.89 [1.4, 2.55] | — | Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002025 | PGS000780 (PRS135_allergy) |
PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Atopic March | — | — | Relative Risk Ratio (RRR): 1.99 [1.74, 2.29] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002026 | PGS000780 (PRS135_allergy) |
PSS001008| Ancestry Not Reported| 897 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Persistent eczema and wheeze | — | — | Relative Risk Ratio (RRR): 1.38 [1.01, 1.9] | — | Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002027 | PGS000780 (PRS135_allergy) |
PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Persistent eczema and wheeze | — | — | Relative Risk Ratio (RRR): 1.39 [1.22, 1.6] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002028 | PGS000780 (PRS135_allergy) |
PSS001008| Ancestry Not Reported| 897 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Persistent eczema with late-onset rhinitis | — | — | Relative Risk Ratio (RRR): 1.35 [1.04, 1.76] | — | Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002029 | PGS000780 (PRS135_allergy) |
PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Persistent eczema with late-onset rhinitis | — | — | Relative Risk Ratio (RRR): 1.51 [1.35, 1.68] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002030 | PGS000780 (PRS135_allergy) |
PSS001008| Ancestry Not Reported| 897 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Persistent wheeze with late-onset rhinitis | — | — | Relative Risk Ratio (RRR): 1.58 [1.22, 2.03] | — | Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002031 | PGS000780 (PRS135_allergy) |
PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Persistent wheeze with late-onset rhinitis | — | — | Relative Risk Ratio (RRR): 1.44 [1.3, 1.6] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002032 | PGS000780 (PRS135_allergy) |
PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Transient wheeze | — | — | Relative Risk Ratio (RRR): 1.11 [1.02, 1.21] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002033 | PGS000780 (PRS135_allergy) |
PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Eczema only | — | — | Relative Risk Ratio (RRR): 1.16 [1.08, 1.24] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002034 | PGS000780 (PRS135_allergy) |
PSS001008| Ancestry Not Reported| 897 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Rhinitis only | — | — | Relative Risk Ratio (RRR): 1.32 [1.06, 1.64] | — | Only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002035 | PGS000780 (PRS135_allergy) |
PSS001007| Multi-ancestry (including European)| 7,242 individuals |
PGP000184 | Clark H et al. Clin Exp Allergy (2019) |
Reported Trait: Rhinitis only | — | — | Relative Risk Ratio (RRR): 1.21 [1.12, 1.31] | — | For the MAAS cohort, only 134 SNPs from the 135 SNP PRS were utilised. Rs10305290 was not included as the SNP was monomorphic. |
| PPM002081 | PGS000800 (GRSw_SHARE) |
PSS001029| European Ancestry| 1,858 individuals |
PGP000189 | Dijk FN et al. J Allergy Clin Immunol (2019) |
Reported Trait: Asthma ever, at age 8 years | OR: 1.72 [1.21, 2.44] | — | — | — | — |
| PPM002083 | PGS000800 (GRSw_SHARE) |
PSS001028| European Ancestry| 427 individuals |
PGP000189 | Dijk FN et al. J Allergy Clin Immunol (2019) |
Reported Trait: Asthma ever, at age 8 years | OR: 4.75 | — | — | — | — |
| PPM002082 | PGS000800 (GRSw_SHARE) |
PSS001029| European Ancestry| 1,858 individuals |
PGP000189 | Dijk FN et al. J Allergy Clin Immunol (2019) |
Reported Trait: Asthma ever, at age 8 years | — | AUROC: 0.65 | — | Familial risk score (factors: parental allergy, parental allergy to pets, parental inhaled medication, low parental education) , environmental risk score (factors: pets at home during pregnancy, smoking mother during pregnancy, older siblings living at home), perinatal risk score (factors: sex, low birth weight < 2500 g) | — |
| PPM002084 | PGS000800 (GRSw_SHARE) |
PSS001028| European Ancestry| 427 individuals |
PGP000189 | Dijk FN et al. J Allergy Clin Immunol (2019) |
Reported Trait: Asthma ever, at age 8 years | — | AUROC: 0.7 | — | Familial risk score (factors: parental allergy, parental allergy to pets, parental inhaled medication, low parental education) , environmental risk score (factors: pets at home during pregnancy, smoking mother during pregnancy, older siblings living at home), perinatal risk score (factors: sex, low birth weight < 2500 g) | — |
| PPM002100 | PGS000803 (wGRS41_SLE) |
PSS001038| European Ancestry| 47,904 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Lupus (localised and systemic) | OR: 1.73 [1.62, 1.85] β: 0.546 (0.034) |
— | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002101 | PGS000803 (wGRS41_SLE) |
PSS001043| European Ancestry| 18,722 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Lupus (localised and systemic) | OR: 1.82 [1.66, 2.0] | — | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002102 | PGS000803 (wGRS41_SLE) |
PSS001035| European Ancestry| 47,917 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Systemic lupus erythematosus | OR: 1.71 [1.6, 1.82] β: 0.534 (0.034) |
— | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002103 | PGS000803 (wGRS41_SLE) |
PSS001040| European Ancestry| 18,698 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Systemic lupus erythematosus | OR: 1.86 [1.69, 2.04] | — | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002104 | PGS000803 (wGRS41_SLE) |
PSS001037| European Ancestry| 50,429 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Erythematous conditions | OR: 1.28 [1.22, 1.34] β: 0.246 (0.024) |
— | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002105 | PGS000803 (wGRS41_SLE) |
PSS001042| European Ancestry| 21,474 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Erythematous conditions | OR: 1.08 [1.04, 1.13] | — | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002106 | PGS000803 (wGRS41_SLE) |
PSS001034| European Ancestry| 47,321 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Cutaneous lupus erythematosus | OR: 1.79 [1.54, 2.08] β: 0.582 (0.078) |
— | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002107 | PGS000803 (wGRS41_SLE) |
PSS001039| European Ancestry| 18,422 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Cutaneous lupus erythematosus | OR: 2.02 [1.71, 2.4] | — | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002108 | PGS000803 (wGRS41_SLE) |
PSS001036| European Ancestry| 40,528 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Type 1 diabetes | OR: 1.11 [1.06, 1.17] β: 0.108 (0.024) |
— | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002109 | PGS000803 (wGRS41_SLE) |
PSS001041| European Ancestry| 19,191 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Type 1 diabetes | OR: 1.11 [1.05, 1.18] | — | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002110 | PGS000803 (wGRS41_SLE) |
PSS001036| European Ancestry| 40,528 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Type 1 diabetes with renal manifestations | OR: 1.41 [1.26, 1.59] β: 0.346 (0.06) |
— | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002111 | PGS000803 (wGRS41_SLE) |
PSS001041| European Ancestry| 19,191 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Type 1 diabetes with renal manifestations | OR: 1.38 [1.19, 1.6] | — | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002112 | PGS000803 (wGRS41_SLE) |
PSS001036| European Ancestry| 40,528 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Type 1 diabetes with opthalmic manifestations | OR: 1.32 [1.16, 1.5] β: 0.275 (0.065) |
— | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002113 | PGS000803 (wGRS41_SLE) |
PSS001041| European Ancestry| 19,191 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Type 1 diabetes with opthalmic manifestations | OR: 1.34 [1.18, 1.52] | — | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002114 | PGS000803 (wGRS41_SLE) |
PSS001036| European Ancestry| 40,528 individuals |
PGP000192 | Kawai VK et al. Lupus (2021) |
Reported Trait: Type 1 diabetes with neurological manifestations | OR: 1.16 [1.06, 1.28] β: 0.151 (0.047) |
— | — | PCs(1-5), median age in the electronic health record, sex | — |
| PPM002160 | PGS000810 (wGRS136_Allergy) |
PSS001055| European Ancestry| 22,029 individuals |
PGP000199 | Ferreira MAR et al. PLoS Genet (2020) |Ext. |
Reported Trait: Asthma age of onset | — | — | Percent (%) of cases with asthma prior to age 16 (bottom 10% of GRS): 14.0 | — | — |
| PPM002161 | PGS000810 (wGRS136_Allergy) |
PSS001055| European Ancestry| 22,029 individuals |
PGP000199 | Ferreira MAR et al. PLoS Genet (2020) |Ext. |
Reported Trait: Asthma age of onset | — | — | Percent (%) of cases with asthma prior to age 16 (top 10% of GRS): 35.0 | — | — |
| PPM002162 | PGS000810 (wGRS136_Allergy) |
PSS001055| European Ancestry| 22,029 individuals |
PGP000199 | Ferreira MAR et al. PLoS Genet (2020) |Ext. |
Reported Trait: Asthma age of onset | — | — | Median age of asthma onset in years (bottom 10% of GRS): 42.0 | — | — |
| PPM002163 | PGS000810 (wGRS136_Allergy) |
PSS001055| European Ancestry| 22,029 individuals |
PGP000199 | Ferreira MAR et al. PLoS Genet (2020) |Ext. |
Reported Trait: Asthma age of onset | — | — | Median age of asthma onset in years (top 10% of GRS): 30.0 | — | — |
| PPM002164 | PGS000810 (wGRS136_Allergy) |
PSS001057| European Ancestry| 14,474 individuals |
PGP000199 | Ferreira MAR et al. PLoS Genet (2020) |Ext. |
Reported Trait: Hay fever age of onset | — | — | Median age of onset in years (bottom 10% of GRS): 25.0 | — | — |
| PPM002165 | PGS000810 (wGRS136_Allergy) |
PSS001057| European Ancestry| 14,474 individuals |
PGP000199 | Ferreira MAR et al. PLoS Genet (2020) |Ext. |
Reported Trait: Hay fever age of onset | — | — | Median age of onset in years (top 10% of GRS): 18.0 | — | — |
| PPM002166 | PGS000810 (wGRS136_Allergy) |
PSS001056| European Ancestry| 3,969 individuals |
PGP000199 | Ferreira MAR et al. PLoS Genet (2020) |Ext. |
Reported Trait: Eczema age of onset | — | — | Median age of onset in years (bottom 10% of GRS): 30.0 | — | — |
| PPM002167 | PGS000810 (wGRS136_Allergy) |
PSS001056| European Ancestry| 3,969 individuals |
PGP000199 | Ferreira MAR et al. PLoS Genet (2020) |Ext. |
Reported Trait: Eczema age of onset | — | — | Median age of onset in years (top 10% of GRS): 23.0 | — | — |
| PPM002411 | PGS000867 (GRS10_Allergy) |
PSS001091| European Ancestry| 1,330 individuals |
PGP000213 | Arabkhazaeli A et al. Pediatr Allergy Immunol (2017) |
Reported Trait: Time to physician-diagnosed allergy in childhood | HR: 1.79 [1.06, 3.02] | — | — | — | — |
| PPM002412 | PGS000867 (GRS10_Allergy) |
PSS001091| European Ancestry| 1,330 individuals |
PGP000213 | Arabkhazaeli A et al. Pediatr Allergy Immunol (2017) |
Reported Trait: Time to physician-diagnosed allergy in childhood | HR: 1.89 [1.05, 3.41] | — | — | Age, gender, breastfeeding, family history of asthma, family history of allergies | — |
| PPM008284 | PGS001109 (GBE_HC1021) |
PSS004069| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vasomotor and allergic rhinitis | — | AUROC: 0.5683 [0.54473, 0.59188] | R²: 0.01206 Incremental AUROC (full-covars): 0.00409 PGS R2 (no covariates): 0.00275 PGS AUROC (no covariates): 0.53243 [0.50926, 0.55561] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008285 | PGS001109 (GBE_HC1021) |
PSS004070| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vasomotor and allergic rhinitis | — | AUROC: 0.54528 [0.51116, 0.5794] | R²: 0.01457 Incremental AUROC (full-covars): 0.00387 PGS R2 (no covariates): 0.00105 PGS AUROC (no covariates): 0.51375 [0.47834, 0.54917] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008286 | PGS001109 (GBE_HC1021) |
PSS004071| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vasomotor and allergic rhinitis | — | AUROC: 0.6003 [0.58786, 0.61273] | R²: 0.0217 Incremental AUROC (full-covars): 0.02658 PGS R2 (no covariates): 0.00981 PGS AUROC (no covariates): 0.56712 [0.55454, 0.57969] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008287 | PGS001109 (GBE_HC1021) |
PSS004072| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vasomotor and allergic rhinitis | — | AUROC: 0.55379 [0.53392, 0.57366] | R²: 0.00762 Incremental AUROC (full-covars): 0.0079 PGS R2 (no covariates): 0.00254 PGS AUROC (no covariates): 0.53239 [0.51256, 0.55222] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008288 | PGS001109 (GBE_HC1021) |
PSS004073| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: TTE vasomotor and allergic rhinitis | — | AUROC: 0.59854 [0.59138, 0.6057] | R²: 0.02303 Incremental AUROC (full-covars): 0.02878 PGS R2 (no covariates): 0.0118 PGS AUROC (no covariates): 0.56998 [0.56268, 0.57727] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008800 | PGS001259 (GBE_HC49) |
PSS004511| African Ancestry| 6,497 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever/allergic rhinitis | — | AUROC: 0.58821 [0.55886, 0.61757] | R²: 0.01784 Incremental AUROC (full-covars): -0.00253 PGS R2 (no covariates): 0.00082 PGS AUROC (no covariates): 0.51547 [0.48626, 0.54467] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008801 | PGS001259 (GBE_HC49) |
PSS004512| East Asian Ancestry| 1,704 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever/allergic rhinitis | — | AUROC: 0.56313 [0.52505, 0.60122] | R²: 0.02281 Incremental AUROC (full-covars): 0.00075 PGS R2 (no covariates): 0.0011 PGS AUROC (no covariates): 0.52627 [0.48539, 0.56716] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008802 | PGS001259 (GBE_HC49) |
PSS004513| European Ancestry| 24,905 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever/allergic rhinitis | — | AUROC: 0.60641 [0.59175, 0.62107] | R²: 0.02043 Incremental AUROC (full-covars): 0.01519 PGS R2 (no covariates): 0.00564 PGS AUROC (no covariates): 0.55414 [0.53891, 0.56936] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008803 | PGS001259 (GBE_HC49) |
PSS004514| South Asian Ancestry| 7,831 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever/allergic rhinitis | — | AUROC: 0.60093 [0.57427, 0.6276] | R²: 0.02041 Incremental AUROC (full-covars): 0.00631 PGS R2 (no covariates): 0.00266 PGS AUROC (no covariates): 0.54086 [0.51259, 0.56913] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008804 | PGS001259 (GBE_HC49) |
PSS004515| European Ancestry| 67,425 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever/allergic rhinitis | — | AUROC: 0.60078 [0.59218, 0.60937] | R²: 0.02042 Incremental AUROC (full-covars): 0.01922 PGS R2 (no covariates): 0.00737 PGS AUROC (no covariates): 0.5597 [0.55096, 0.56843] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008917 | PGS001283 (GBE_INI3761) |
PSS007255| European Ancestry| 13,999 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Age hay fever, rhinitis or eczema diagnosed | — | — | R²: 0.11512 [0.11059, 0.11965] Incremental R2 (full-covars): 0.01247 PGS R2 (no covariates): 0.0125 [0.01084, 0.01417] |
age, sex, UKB array type, Genotype PCs | — |
| PPM008913 | PGS001283 (GBE_INI3761) |
PSS007251| African Ancestry| 1,401 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Age hay fever, rhinitis or eczema diagnosed | — | — | R²: 0.14854 [0.13259, 0.16449] Incremental R2 (full-covars): -0.0075 PGS R2 (no covariates): 0.00033 [-0.00055, 0.0012] |
age, sex, UKB array type, Genotype PCs | — |
| PPM008914 | PGS001283 (GBE_INI3761) |
PSS007252| East Asian Ancestry| 592 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Age hay fever, rhinitis or eczema diagnosed | — | — | R²: 0.08793 [0.0623, 0.11356] Incremental R2 (full-covars): 0.01315 PGS R2 (no covariates): 0.01568 [0.004, 0.02736] |
age, sex, UKB array type, Genotype PCs | — |
| PPM008915 | PGS001283 (GBE_INI3761) |
PSS007253| European Ancestry| 5,147 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Age hay fever, rhinitis or eczema diagnosed | — | — | R²: 0.11614 [0.10866, 0.12362] Incremental R2 (full-covars): 0.01049 PGS R2 (no covariates): 0.01087 [0.00831, 0.01343] |
age, sex, UKB array type, Genotype PCs | — |
| PPM008916 | PGS001283 (GBE_INI3761) |
PSS007254| South Asian Ancestry| 1,451 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Age hay fever, rhinitis or eczema diagnosed | — | — | R²: 0.11629 [0.10294, 0.12963] Incremental R2 (full-covars): 0.00477 PGS R2 (no covariates): 0.00527 [0.00207, 0.00846] |
age, sex, UKB array type, Genotype PCs | — |
| PPM008918 | PGS001284 (GBE_BIN_FC10006152) |
PSS003736| African Ancestry| 6,348 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever allergic rhinitis or eczema | — | AUROC: 0.6114 [0.59586, 0.62694] | R²: 0.04366 Incremental AUROC (full-covars): 0.00507 PGS R2 (no covariates): 0.0072 PGS AUROC (no covariates): 0.5418 [0.52577, 0.55784] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008919 | PGS001284 (GBE_BIN_FC10006152) |
PSS003737| East Asian Ancestry| 1,640 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever allergic rhinitis or eczema | — | AUROC: 0.6017 [0.57412, 0.62927] | R²: 0.04656 Incremental AUROC (full-covars): 0.01162 PGS R2 (no covariates): 0.01108 PGS AUROC (no covariates): 0.55514 [0.52697, 0.58332] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008920 | PGS001284 (GBE_BIN_FC10006152) |
PSS003738| European Ancestry| 24,838 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever allergic rhinitis or eczema | — | AUROC: 0.63382 [0.62577, 0.64186] | R²: 0.06149 Incremental AUROC (full-covars): 0.03904 PGS R2 (no covariates): 0.0337 PGS AUROC (no covariates): 0.60011 [0.59191, 0.60831] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008921 | PGS001284 (GBE_BIN_FC10006152) |
PSS003739| South Asian Ancestry| 7,556 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever allergic rhinitis or eczema | — | AUROC: 0.60105 [0.58571, 0.6164] | R²: 0.03149 Incremental AUROC (full-covars): 0.04131 PGS R2 (no covariates): 0.02118 PGS AUROC (no covariates): 0.58123 [0.56584, 0.59661] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008922 | PGS001284 (GBE_BIN_FC10006152) |
PSS003740| European Ancestry| 67,349 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever allergic rhinitis or eczema | — | AUROC: 0.63735 [0.6325, 0.6422] | R²: 0.06354 Incremental AUROC (full-covars): 0.05347 PGS R2 (no covariates): 0.04086 PGS AUROC (no covariates): 0.60988 [0.60494, 0.61483] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008923 | PGS001285 (GBE_BIN_FC5006152) |
PSS003979| African Ancestry| 5,863 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever rhinitis or eczema diagnosed by doctor | — | AUROC: 0.61988 [0.60418, 0.63557] | R²: 0.05243 Incremental AUROC (full-covars): 0.00361 PGS R2 (no covariates): 0.00809 PGS AUROC (no covariates): 0.5435 [0.52719, 0.55982] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008924 | PGS001285 (GBE_BIN_FC5006152) |
PSS003980| East Asian Ancestry| 1,575 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever rhinitis or eczema diagnosed by doctor | — | AUROC: 0.60016 [0.57208, 0.62825] | R²: 0.04666 Incremental AUROC (full-covars): 0.00725 PGS R2 (no covariates): 0.0103 PGS AUROC (no covariates): 0.55278 [0.52414, 0.58142] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008925 | PGS001285 (GBE_BIN_FC5006152) |
PSS003981| European Ancestry| 22,705 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever rhinitis or eczema diagnosed by doctor | — | AUROC: 0.64037 [0.63223, 0.64852] | R²: 0.07055 Incremental AUROC (full-covars): 0.04919 PGS R2 (no covariates): 0.04448 PGS AUROC (no covariates): 0.61233 [0.60403, 0.62062] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008926 | PGS001285 (GBE_BIN_FC5006152) |
PSS003982| South Asian Ancestry| 6,933 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever rhinitis or eczema diagnosed by doctor | — | AUROC: 0.61 [0.59463, 0.62537] | R²: 0.03824 Incremental AUROC (full-covars): 0.05029 PGS R2 (no covariates): 0.02803 PGS AUROC (no covariates): 0.59248 [0.57698, 0.60797] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008927 | PGS001285 (GBE_BIN_FC5006152) |
PSS003983| European Ancestry| 61,525 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Hayfever rhinitis or eczema diagnosed by doctor | — | AUROC: 0.64412 [0.63921, 0.64903] | R²: 0.07281 Incremental AUROC (full-covars): 0.06352 PGS R2 (no covariates): 0.05108 PGS AUROC (no covariates): 0.62052 [0.61552, 0.62551] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008928 | PGS001286 (GBE_BIN22126) |
PSS003671| African Ancestry| 516 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Doctor diagnosed hayfever or allergic rhinitis | — | AUROC: 0.59048 [0.53845, 0.6425] | R²: 0.04417 Incremental AUROC (full-covars): -0.00133 PGS R2 (no covariates): 0.0 PGS AUROC (no covariates): 0.49458 [0.44138, 0.54777] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008929 | PGS001286 (GBE_BIN22126) |
PSS003672| East Asian Ancestry| 245 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Doctor diagnosed hayfever or allergic rhinitis | — | AUROC: 0.64171 [0.57232, 0.7111] | R²: 0.10104 Incremental AUROC (full-covars): 0.0021 PGS R2 (no covariates): 0.00195 PGS AUROC (no covariates): 0.53214 [0.45762, 0.60665] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008930 | PGS001286 (GBE_BIN22126) |
PSS003673| European Ancestry| 5,959 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Doctor diagnosed hayfever or allergic rhinitis | — | AUROC: 0.57725 [0.56045, 0.59405] | R²: 0.02043 Incremental AUROC (full-covars): 0.01152 PGS R2 (no covariates): 0.00603 PGS AUROC (no covariates): 0.53991 [0.52259, 0.55722] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008931 | PGS001286 (GBE_BIN22126) |
PSS003674| South Asian Ancestry| 707 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Doctor diagnosed hayfever or allergic rhinitis | — | AUROC: 0.62831 [0.58265, 0.67397] | R²: 0.06246 Incremental AUROC (full-covars): 0.0031 PGS R2 (no covariates): 0.00591 PGS AUROC (no covariates): 0.54034 [0.49224, 0.58845] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM008932 | PGS001286 (GBE_BIN22126) |
PSS003675| European Ancestry| 17,244 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Doctor diagnosed hayfever or allergic rhinitis | — | AUROC: 0.59244 [0.58227, 0.60261] | R²: 0.02888 Incremental AUROC (full-covars): 0.02256 PGS R2 (no covariates): 0.01469 PGS AUROC (no covariates): 0.56502 [0.55474, 0.5753] |
age, sex, UKB array type, Genotype PCs | Full Model & PGS R2 is estimated using Nagelkerke's method |
| PPM005290 | PGS001372 (GBE_INI22146) |
PSS004956| African Ancestry| 170 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Age hayfever or allergic rhinitis diagnosed by doctor | — | — | R²: 0.13957 [0.12394, 0.15519] Incremental R2 (full-covars): -0.01335 PGS R2 (no covariates): 0.00276 [0.00021, 0.00531] |
age, sex, UKB array type, Genotype PCs | — |
| PPM005291 | PGS001372 (GBE_INI22146) |
PSS004957| East Asian Ancestry| 106 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Age hayfever or allergic rhinitis diagnosed by doctor | — | — | R²: 0.0439 [0.02492, 0.06289] Incremental R2 (full-covars): -0.00185 PGS R2 (no covariates): 0.00016 [-0.00104, 0.00135] |
age, sex, UKB array type, Genotype PCs | — |
| PPM005292 | PGS001372 (GBE_INI22146) |
PSS004958| European Ancestry| 1,421 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Age hayfever or allergic rhinitis diagnosed by doctor | — | — | R²: 0.098 [0.09099, 0.10502] Incremental R2 (full-covars): 0.00684 PGS R2 (no covariates): 0.00657 [0.00457, 0.00857] |
age, sex, UKB array type, Genotype PCs | — |
| PPM005293 | PGS001372 (GBE_INI22146) |
PSS004959| South Asian Ancestry| 187 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Age hayfever or allergic rhinitis diagnosed by doctor | — | — | R²: 0.20226 [0.18637, 0.21814] Incremental R2 (full-covars): 0.01767 PGS R2 (no covariates): 0.01185 [0.00708, 0.01661] |
age, sex, UKB array type, Genotype PCs | — |
| PPM005294 | PGS001372 (GBE_INI22146) |
PSS004960| European Ancestry| 3,857 individuals |
PGP000244 | Tanigawa Y et al. PLoS Genet (2022) |
Reported Trait: Age hayfever or allergic rhinitis diagnosed by doctor | — | — | R²: 0.08334 [0.07935, 0.08734] Incremental R2 (full-covars): 0.00599 PGS R2 (no covariates): 0.00511 [0.00404, 0.00619] |
age, sex, UKB array type, Genotype PCs | — |
| PPM009229 | PGS001773 (PRS_atopicDermatitis) |
PSS007661| Multi-ancestry (including European)| 676 individuals |
PGP000253 | Simard M et al. J Allergy Clin Immunol (2020) |
Reported Trait: Moderate-to-severe aotpic dermatitis | — | AUROC: 0.93 | R²: 0.49 | Age, sex, father's ethnicity, mother ethnicity | Nagelkerke's R^2, only unrelated individuals were considered in the analyses |
| PPM009230 | PGS001773 (PRS_atopicDermatitis) |
PSS007661| Multi-ancestry (including European)| 676 individuals |
PGP000253 | Simard M et al. J Allergy Clin Immunol (2020) |
Reported Trait: Food allergy | — | AUROC: 0.75 | — | Age, sex, father's ethnicity, mother ethnicity | Only unrelated individuals were considered in the analyses |
| PPM009231 | PGS001773 (PRS_atopicDermatitis) |
PSS007661| Multi-ancestry (including European)| 676 individuals |
PGP000253 | Simard M et al. J Allergy Clin Immunol (2020) |
Reported Trait: Allergic asthma | — | AUROC: 0.75 | — | Age, sex, father's ethnicity, mother ethnicity | Only unrelated individuals were considered in the analyses |
| PPM009232 | PGS001773 (PRS_atopicDermatitis) |
PSS007661| Multi-ancestry (including European)| 676 individuals |
PGP000253 | Simard M et al. J Allergy Clin Immunol (2020) |
Reported Trait: Allergic rhinitis | — | AUROC: 0.77 | — | Age, sex, father's ethnicity, mother ethnicity | Only unrelated individuals were considered in the analyses |
| PPM009964 | PGS001885 (portability-PLR_960.2) |
PSS009362| European Ancestry| 19,352 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): 0.0296 [0.0155, 0.0436] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009966 | PGS001885 (portability-PLR_960.2) |
PSS008690| European Ancestry| 6,493 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): 0.0196 [-0.0047, 0.044] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009967 | PGS001885 (portability-PLR_960.2) |
PSS008464| Greater Middle Eastern Ancestry| 1,172 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): -0.0358 [-0.0933, 0.022] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009968 | PGS001885 (portability-PLR_960.2) |
PSS008244| South Asian Ancestry| 6,180 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): -0.0111 [-0.036, 0.0139] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009969 | PGS001885 (portability-PLR_960.2) |
PSS008022| East Asian Ancestry| 1,773 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): -0.0272 [-0.0739, 0.0196] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009970 | PGS001885 (portability-PLR_960.2) |
PSS007808| African Ancestry| 2,406 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): 0.0141 [-0.0261, 0.0542] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009971 | PGS001885 (portability-PLR_960.2) |
PSS008912| African Ancestry| 3,818 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): 0.0003 [-0.0315, 0.0321] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM009965 | PGS001885 (portability-PLR_960.2) |
PSS009136| European Ancestry| 4,025 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): 0.0128 [-0.0182, 0.0437] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011632 | PGS002097 (portability-ldpred2_960.2) |
PSS009362| European Ancestry| 19,352 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): 0.0397 [0.0256, 0.0537] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011633 | PGS002097 (portability-ldpred2_960.2) |
PSS009136| European Ancestry| 4,025 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): 0.0394 [0.0085, 0.0703] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011635 | PGS002097 (portability-ldpred2_960.2) |
PSS008464| Greater Middle Eastern Ancestry| 1,172 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): -0.0396 [-0.0971, 0.0182] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011636 | PGS002097 (portability-ldpred2_960.2) |
PSS008244| South Asian Ancestry| 6,180 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): 0.0264 [0.0015, 0.0514] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011637 | PGS002097 (portability-ldpred2_960.2) |
PSS008022| East Asian Ancestry| 1,773 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): -0.0013 [-0.0481, 0.0455] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011638 | PGS002097 (portability-ldpred2_960.2) |
PSS007808| African Ancestry| 2,406 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): -0.0128 [-0.0529, 0.0273] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011639 | PGS002097 (portability-ldpred2_960.2) |
PSS008912| African Ancestry| 3,818 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): 0.0043 [-0.0275, 0.0361] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM011634 | PGS002097 (portability-ldpred2_960.2) |
PSS008690| European Ancestry| 6,493 individuals |
PGP000263 | Privé F et al. Am J Hum Genet (2022) |
Reported Trait: Allergy/adverse effect of penicillin | — | — | Partial Correlation (partial-r): 0.0313 [0.0069, 0.0556] | sex, age, birth date, deprivation index, 16 PCs | — |
| PPM014955 | PGS002755 (Atopic_dermatitis_prscs) |
PSS009939| European Ancestry| 39,444 individuals |
PGP000364 | Mars N et al. Am J Hum Genet (2022) |
Reported Trait: Atopic dermatitis | OR: 1.28 [1.21, 1.34] | — | — | age, sex, 10 PCs, technical covariates | — |
| PPM020709 | PGS002755 (Atopic_dermatitis_prscs) |
PSS011376| European Ancestry| 337,910 individuals |
PGP000566 | Gu X et al. Ecotoxicol Environ Saf (2023) |Ext. |
Reported Trait: Incident atopic dermatitis | — | — | Hazard ratio (HR, high vs low PRS): 1.249 [1.123, 1.391] | sex, age, Townsend index, moderate physical and household income | — |
| PPM020710 | PGS002755 (Atopic_dermatitis_prscs) |
PSS011376| European Ancestry| 337,910 individuals |
PGP000566 | Gu X et al. Ecotoxicol Environ Saf (2023) |Ext. |
Reported Trait: Incident atopic dermatitis with air pollution level | — | — | Hazard ratio (HR, high air pollution and high PRS vs low air pollution and low PRS): 1.978 [1.624, 2.411] | sex, age, Townsend index, moderate physical and household income | — |
| PPM017413 | PGS003458 (PRS_AT) |
PSS010186| European Ancestry| 3,212 individuals |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
Reported Trait: Paradoxical eczema in biologic-treated psoriasis | OR: 2.24 [1.2, 4.17] | AUROC: 0.583 | — | PCs 1-2 | — |
| PPM017414 | PGS003459 (PRS_CO) |
PSS010186| European Ancestry| 3,212 individuals |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
Reported Trait: Paradoxical eczema in biologic-treated psoriasis | OR: 1.83 [1.17, 2.84] | AUROC: 0.585 | — | PCs 1-2 | — |
| PPM017412 | PGS003486 (PRS_AE) |
PSS010186| European Ancestry| 3,212 individuals |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
Reported Trait: Paradoxical eczema in biologic-treated psoriasis | OR: 1.89 [1.08, 3.3] | AUROC: 0.567 | — | PCs 1-2 | — |
| PPM017415 | PGS003487 (PRS_IL4) |
PSS010186| European Ancestry| 3,212 individuals |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
Reported Trait: Paradoxical eczema in biologic-treated psoriasis | OR: 2.08 [0.7, 6.06] | — | — | PCs 1-2 | — |
| PPM017416 | PGS003488 (PRS_IL12) |
PSS010186| European Ancestry| 3,212 individuals |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
Reported Trait: Paradoxical eczema in biologic-treated psoriasis | OR: 4.89 [1.03, 23.29] | — | — | PCs 1-2 | — |
| PPM017417 | PGS003489 (PRS_IL17) |
PSS010186| European Ancestry| 3,212 individuals |
PGP000451 | Al-Janabi A et al. J Invest Dermatol (2023) |
Reported Trait: Paradoxical eczema in biologic-treated psoriasis | OR: 1.55 [0.47, 5.14] | — | — | PCs 1-2 | — |
| PPM018525 | PGS003755 (wGRS_SLE) |
PSS011006| East Asian Ancestry| 1,655 individuals |
PGP000475 | Kwon YC et al. Arthritis Rheumatol (2023) |
Reported Trait: Class III/IV lupus nephritis in anti-sm positive systemic lupus erythematosus | — | AUROC: 0.582 [0.496, 0.668] | — | — | — |
| PPM018519 | PGS003755 (wGRS_SLE) |
PSS011006| East Asian Ancestry| 1,655 individuals |
PGP000475 | Kwon YC et al. Arthritis Rheumatol (2023) |
Reported Trait: Childhood-onset systemic lupus erythematosus (onset at age <16 years) | — | — | p: 6.80e-08 | — | — |
| PPM018520 | PGS003755 (wGRS_SLE) |
PSS011006| East Asian Ancestry| 1,655 individuals |
PGP000475 | Kwon YC et al. Arthritis Rheumatol (2023) |
Reported Trait: Number of American College of Rheumatology (ACR) criteria for systemic lupus erythematosus | β: 0.143 [0.078, 0.208] | — | — | Onset age, sex, disease duration, and top 4 principal components | — |
| PPM018523 | PGS003755 (wGRS_SLE) |
PSS011006| East Asian Ancestry| 1,655 individuals |
PGP000475 | Kwon YC et al. Arthritis Rheumatol (2023) |
Reported Trait: Renal disorder | β: 1.22 [1.12, 1.33] | — | — | Onset age, sex, disease duration, and top 4 principal components | — |
| PPM018524 | PGS003755 (wGRS_SLE) |
PSS011006| East Asian Ancestry| 1,655 individuals |
PGP000475 | Kwon YC et al. Arthritis Rheumatol (2023) |
Reported Trait: Production of anti-Sm antibody | β: 1.23 [1.11, 1.36] | — | — | Onset age, sex, disease duration, and top 4 principal components | — |
| PPM018526 | PGS003755 (wGRS_SLE) |
PSS011006| East Asian Ancestry| 1,655 individuals |
PGP000475 | Kwon YC et al. Arthritis Rheumatol (2023) |
Reported Trait: Class V lupus nephritis in anti-sm positive systemic lupus erythematosus | — | AUROC: 0.681 [0.602, 0.76] | — | — | — |
| PPM018521 | PGS003756 (wGRS_SLE_non-HLA) |
PSS011006| East Asian Ancestry| 1,655 individuals |
PGP000475 | Kwon YC et al. Arthritis Rheumatol (2023) |
Reported Trait: Number of American College of Rheumatology (ACR) criteria for systemic lupus erythematosus | β: 0.133 [0.071, 0.194] | — | — | Onset age, sex, disease duration, and top 4 principal components | — |
| PPM018522 | PGS003757 (wGRS_SLE_HLA) |
PSS011006| East Asian Ancestry| 1,655 individuals |
PGP000475 | Kwon YC et al. Arthritis Rheumatol (2023) |
Reported Trait: Number of American College of Rheumatology (ACR) criteria for systemic lupus erythematosus | β: 0.213 [0.079, 0.347] | — | — | Onset age, sex, disease duration, and top 4 principal components | — |
| PPM019115 | PGS003960 (GRS57_SLE) |
PSS011186| Multi-ancestry (including European)| 3,048 individuals |
PGP000509 | Barnado A et al. Arthritis Rheumatol (2023) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.65 [0.63, 0.67] | — | — | — |
| PPM019116 | PGS003960 (GRS57_SLE) |
PSS011188| European Ancestry| 1,994 individuals |
PGP000509 | Barnado A et al. Arthritis Rheumatol (2023) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.63 [0.6, 0.66] | — | — | — |
| PPM019117 | PGS003960 (GRS57_SLE) |
PSS011187| African Ancestry| 902 individuals |
PGP000509 | Barnado A et al. Arthritis Rheumatol (2023) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.5 [0.44, 0.56] | — | — | — |
| PPM019118 | PGS003960 (GRS57_SLE) |
PSS011186| Multi-ancestry (including European)| 3,048 individuals |
PGP000509 | Barnado A et al. Arthritis Rheumatol (2023) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.89 [0.87, 0.9] | — | phenotype risk score | — |
| PPM019119 | PGS003960 (GRS57_SLE) |
PSS011188| European Ancestry| 1,994 individuals |
PGP000509 | Barnado A et al. Arthritis Rheumatol (2023) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.87 [0.85, 0.89] | — | phenotype risk score | — |
| PPM019120 | PGS003960 (GRS57_SLE) |
PSS011187| African Ancestry| 902 individuals |
PGP000509 | Barnado A et al. Arthritis Rheumatol (2023) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.89 [0.86, 0.93] | — | phenotype risk score | — |
| PPM020707 | PGS004587 (PRS23_AD) |
PSS011376| European Ancestry| 337,910 individuals |
PGP000566 | Gu X et al. Ecotoxicol Environ Saf (2023) |
Reported Trait: Incident atopic dermatitis | — | — | Hazard ratio (HR, high vs low PRS): 1.153 [1.037, 1.282] | sex, age, Townsend index, moderate physical and household income | — |
| PPM020708 | PGS004587 (PRS23_AD) |
PSS011376| European Ancestry| 337,910 individuals |
PGP000566 | Gu X et al. Ecotoxicol Environ Saf (2023) |
Reported Trait: Incident atopic dermatitis with air pollution level | — | — | Hazard ratio (HR, high air pollution and high PRS vs low air pollution and low PRS): 1.523 [1.259, 1.84] | sex, age, Townsend index, moderate physical and household income | — |
| PPM021335 | PGS004903 (PRS_ALL) |
PSS011691| European Ancestry| 3,212 individuals |
PGP000633 | Al-Janabi A et al. J Allergy Clin Immunol (2023) |
Reported Trait: Paradoxical eczema in individuals with psoriasis | — | — | Coefficient: 4.77 [0.58, 8.96] p: 0.026 |
— | — |
| PPM021383 | PGS004917 (wGRS) |
PSS011718| Multi-ancestry (including European)| 3,945 individuals |
PGP000648 | Cui J et al. Arthritis Rheumatol (2020) |
Reported Trait: Systemic lupus erythematosus | OR: 2.01 [1.83, 2.22] β: 0.7 (0.05) |
AUROC: 0.696 | — | — | — |
| PPM037457 | PGS019275 (TPMI_476_Lassosum2) |
PSS013178| East Asian Ancestry| 17,583 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Allergic rhinitis | — | AUROC: 0.66159 | R²: 0.1223 | sex, age, array, PCs 1-10 | — |
| PPM037458 | PGS019276 (TPMI_476_LDpred2) |
PSS013177| East Asian Ancestry| 17,583 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Allergic rhinitis | — | AUROC: 0.66228 | R²: 0.12353 | sex, age, array, PCs 1-10 | — |
| PPM037459 | PGS019277 (TPMI_476_MegaPRS) |
PSS013179| East Asian Ancestry| 17,583 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Allergic rhinitis | — | AUROC: 0.66233 | R²: 0.12293 | sex, age, array, PCs 1-10 | — |
| PPM037460 | PGS019278 (TPMI_476_PRS-CS) |
PSS013180| East Asian Ancestry| 17,583 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Allergic rhinitis | — | AUROC: 0.66181 | R²: 0.12306 | sex, age, array, PCs 1-10 | — |
| PPM037461 | PGS019279 (TPMI_476_SBayesR) |
PSS013181| East Asian Ancestry| 17,583 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Allergic rhinitis | — | AUROC: 0.66246 | R²: 0.12377 | sex, age, array, PCs 1-10 | — |
| PPM037775 | PGS019593 (TPMI_695.4_Lassosum2) |
PSS013496| East Asian Ancestry| 18,341 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Lupus localized and systemic | — | AUROC: 0.86928 | R²: 0.16491 | sex, age, array, PCs 1-10 | — |
| PPM037776 | PGS019594 (TPMI_695.4_LDpred2) |
PSS013495| East Asian Ancestry| 18,341 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Lupus localized and systemic | — | AUROC: 0.87217 | R²: 0.16862 | sex, age, array, PCs 1-10 | — |
| PPM037777 | PGS019595 (TPMI_695.4_MegaPRS) |
PSS013497| East Asian Ancestry| 18,341 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Lupus localized and systemic | — | AUROC: 0.86402 | R²: 0.15741 | sex, age, array, PCs 1-10 | — |
| PPM037778 | PGS019596 (TPMI_695.4_PRS-CS) |
PSS013498| East Asian Ancestry| 18,341 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Lupus localized and systemic | — | AUROC: 0.8675 | R²: 0.16203 | sex, age, array, PCs 1-10 | — |
| PPM037779 | PGS019597 (TPMI_695.4_PRSmix+) |
PSS013499| East Asian Ancestry| 18,341 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Lupus localized and systemic | — | AUROC: 0.87785 | R²: 0.17391 | sex, age, array, PCs 1-10 | — |
| PPM037780 | PGS019598 (TPMI_695.4_SBayesR) |
PSS013500| East Asian Ancestry| 18,341 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Lupus localized and systemic | — | AUROC: 0.86676 | R²: 0.15951 | sex, age, array, PCs 1-10 | — |
| PPM037781 | PGS019599 (TPMI_695.42_Lassosum2) |
PSS013490| East Asian Ancestry| 18,328 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.87303 | R²: 0.16342 | sex, age, array, PCs 1-10 | — |
| PPM037782 | PGS019600 (TPMI_695.42_LDpred2) |
PSS013489| East Asian Ancestry| 18,328 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.87535 | R²: 0.1665 | sex, age, array, PCs 1-10 | — |
| PPM037783 | PGS019601 (TPMI_695.42_MegaPRS) |
PSS013491| East Asian Ancestry| 18,328 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.86743 | R²: 0.15497 | sex, age, array, PCs 1-10 | — |
| PPM037784 | PGS019602 (TPMI_695.42_PRS-CS) |
PSS013492| East Asian Ancestry| 18,328 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.87012 | R²: 0.15989 | sex, age, array, PCs 1-10 | — |
| PPM037785 | PGS019603 (TPMI_695.42_PRSmix+) |
PSS013493| East Asian Ancestry| 18,328 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.88213 | R²: 0.17211 | sex, age, array, PCs 1-10 | — |
| PPM037786 | PGS019604 (TPMI_695.42_SBayesR) |
PSS013494| East Asian Ancestry| 18,328 individuals |
PGP000835 | Chen HH et al. Nature (2025) |
Reported Trait: Systemic lupus erythematosus | — | AUROC: 0.87186 | R²: 0.1582 | sex, age, array, PCs 1-10 | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS011691 | — | — | [
|
— | European | — | BSTOP | — |
| PSS007251 | — | — | 1,401 individuals | — | African unspecified | — | UKB | — |
| PSS007252 | — | — | 592 individuals | — | East Asian | — | UKB | — |
| PSS007253 | — | — | 5,147 individuals | — | European | non-white British ancestry | UKB | — |
| PSS007254 | — | — | 1,451 individuals | — | South Asian | — | UKB | — |
| PSS007255 | — | — | 13,999 individuals | — | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS003671 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS003672 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS003673 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS003674 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS003675 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS008690 | — | — | 6,493 individuals | — | European | Italy (South Europe) | UKB | — |
| PSS013489 | 710.0,M32 | — | [ ,
46.04 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013490 | 710.0,M32 | — | [ ,
46.04 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013491 | 710.0,M32 | — | [ ,
46.04 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013492 | 710.0,M32 | — | [ ,
46.04 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013493 | 710.0,M32 | — | [ ,
46.04 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013494 | 710.0,M32 | — | [ ,
46.04 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013495 | 373.34, 695.4, 710.0,H01.12, L93, M32 | — | [ ,
46.02 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013496 | 373.34, 695.4, 710.0,H01.12, L93, M32 | — | [ ,
46.02 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013497 | 373.34, 695.4, 710.0,H01.12, L93, M32 | — | [ ,
46.02 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013498 | 373.34, 695.4, 710.0,H01.12, L93, M32 | — | [ ,
46.02 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013499 | 373.34, 695.4, 710.0,H01.12, L93, M32 | — | [ ,
46.02 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013500 | 373.34, 695.4, 710.0,H01.12, L93, M32 | — | [ ,
46.02 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS011718 | Those indicating having received a new systemic lupus erythematosus diagnosis were asked to complete the Connective Tissue Disease Screening Question- naire (12) and to consent to the release of their medical records. Released medical records of all nurses who indicated experi- encing systemic lupus erythematosus symptoms on this questionnaire were independently reviewed by 3 board-certified rheumatologists (EWK, JAS, and KHC). Cases of systemic lupus erythematosus were identified based on the presence of at least 4 criteria from the American College of Rheumatology (ACR) 1997 updated criteria for the classification of SLE and also based on reviewers' consensus. | — | [ ,
0.0 % Male samples |
— | European, Not reported | European (98%) | NHS, NHS2 | — |
| PSS011718 | All patients diagnosed as having systemic lupus erythematosus in the PHB and included in this study met at least 4 of the 11 ACR 1997 updated classification criteria for systemic lupus erythematosus . Cases were identified as those individuals previously included in the Brigham and Women's Hospital Lupus Registry or those with ≥3 Interna- tional Classification of Diseases, Ninth Revision (ICD-9)/ICD-10 codes for systemic lupus erythematosus , each noted ≥30 days apart, followed by medical record review to identify the presence of any of the ACR 1997 criteria for systemic lupus erythematosus. | — | [ ,
9.7 % Male samples |
— | European, Asian unspecified, African unspecified, Not reported | European (68.1%), Asian (4.9%), African (14.2%), Not reported (12.8%) | PHB | — |
| PSS000993 | All individuals had systemic lupus erythematosus. Cases are individuals that also have renal disease | — | [
|
— | European | — | NR | — |
| PSS000994 | All individuals had systemic lupus erythematosus. Cases are individuals that also have renal disease | — | [
|
— | European | — | NR | Cases and controls obtained by SLEGEN. |
| PSS003736 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS003737 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS003738 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS003739 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS003740 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS000436 | The discovery cohort included 1001 patients from the University clinics in Uppsala, Linköping, Karolinska Institute (Stockholm), Lund, and from the four northern-most counties in Sweden. All subjects fulfilled ≥4 ACR-82 classification criteria for SLE and were of European descent.30 Clinical data were collected from the patients’ medical files, including SDI scores, the ACR-82 classification criteria, clinical antiphospholipid syndrome (APS) diagnosis, glomerular filtration rate, chronic kidney disease (CKD) stages, ESRD, renal biopsy data and CVE, defined as myocardial infarction, ischaemic cerebrovascular disease or venous thromboembolism (VTE). Control individuals were healthy blood donors from Uppsala (Uppsala Bioresource) and Lund or population based controls from Stockholm and the four northernmost counties of Sweden. | — | [
|
— | European | — | Karolinska, UHU | The discovery cohort included 1001 patients from the University clinics in Uppsala, Linköping, Karolinska Institute (Stockholm), Lund, and from the four northern-most counties in Sweden |
| PSS000437 | The discovery cohort included 1001 patients from the University clinics in Uppsala, Linköping, Karolinska Institute (Stockholm), Lund, and from the four northern-most counties in Sweden. All subjects fulfilled ≥4 ACR-82 classification criteria for SLE and were of European descent.30 Clinical data were collected from the patients’ medical files, including SDI scores, the ACR-82 classification criteria, clinical antiphospholipid syndrome (APS) diagnosis, glomerular filtration rate, chronic kidney disease (CKD) stages, ESRD, renal biopsy data and CVE, defined as myocardial infarction, ischaemic cerebrovascular disease or venous thromboembolism (VTE). | — | [
|
— | European | — | Karolinska, UHU | The discovery cohort included 1001 patients from the University clinics in Uppsala, Linköping, Karolinska Institute (Stockholm), Lund, and from the four northern-most counties in Sweden |
| PSS000438 | — | — | [
|
— | European | — | NR | The replication cohort is described in Langefeld et al. (PMID:28714469) |
| PSS008244 | — | — | 6,180 individuals | — | South Asian | India (South Asia) | UKB | — |
| PSS001007 | Cases were individuals with latent classes of allergic diseases (LCADs). LCADs includes atopic march (defined as having a high probability of eczema from infancy to age 11 years with increased probability of wheeze overtime. For rhinitis, the probability increases from zero at age 1 year to almost 100% by 8 years. Eczema developed first, followed by wheeze, and then rhinitis) , persistent eczema and wheeze (defined as having a similar probability of wheeze and eczema throughout childhood, likely as co-morbidities, with a low probability of rhinitis throughout childhood), persistent eczema with late‐onset rhinitis (defined as having increased eczema prevalence from ~70% in early life to 95% at age 5 years, with little resolution at 11 years. The probability of rhinitis increases to almost 100% by age 8 years with low probability of wheeze throughout childhood), persistent wheeze with late‐onset rhinitis (definned as having a high probability of wheeze throughout childhood, with increasing probability of rhinitis to almost 100% by age 11 years. Probability of eczema being low, declining steadily at age 11 years), transient wheeze (defined as having a high probability of wheeze within the first 5 years, with remission by age 8 years, and a very low probability of eczema and rhinitis throughout childhood), eczema only (defined as having a high probability of eczema throughout life, peaking at ~80% at age 5 years, then declining steadily to a 50% probability at age 11 years) and rhinitis only (defined as having an increasing probability of rhinitis from age 5 to 11 years, but no wheeze or eczema). Of the 575 cases, 230 had atopic march, 227 had persistent eczema and wheeze, 380 had persistent eczema with late-onset rhinitis, 429 had persistent wheeze with late-onset rhinitis, 599 had transient wheeze, 1089 had eczema only and 791 had rhinitis only. | — | [ ,
51.45 % Male samples |
— | European, NR | European = 6345, NR = 897 | ALSPAC, MAAS | Possible sample overlap (up to 88%) between this dataset and the dataset used to source variants for the PRS. |
| PSS001008 | Cases were individuals with latent classes of allergic diseases (LCADs). LCADs includes atopic march (defined as having a high probability of eczema from infancy to age 11 years with increased probability of wheeze overtime. For rhinitis, the probability increases from zero at age 1 year to almost 100% by 8 years. Eczema developed first, followed by wheeze, and then rhinitis) , persistent eczema and wheeze (defined as having a similar probability of wheeze and eczema throughout childhood, likely as co-morbidities, with a low probability of rhinitis throughout childhood), persistent eczema with late‐onset rhinitis (defined as having increased eczema prevalence from ~70% in early life to 95% at age 5 years, with little resolution at 11 years. The probability of rhinitis increases to almost 100% by age 8 years with low probability of wheeze throughout childhood), persistent wheeze with late‐onset rhinitis (definned as having a high probability of wheeze throughout childhood, with increasing probability of rhinitis to almost 100% by age 11 years. Probability of eczema being low, declining steadily at age 11 years), transient wheeze (defined as having a high probability of wheeze within the first 5 years, with remission by age 8 years, and a very low probability of eczema and rhinitis throughout childhood), eczema only (defined as having a high probability of eczema throughout life, peaking at ~80% at age 5 years, then declining steadily to a 50% probability at age 11 years) and rhinitis only (defined as having an increasing probability of rhinitis from age 5 to 11 years, but no wheeze or eczema). Of the 575 cases, 55 had atopic march, 46 had persistent eczema and wheeze, 73 had persistent eczema with late-onset rhinitis, 81 had persistent wheeze with late-onset rhinitis, 65 had transient wheeze, 141 had eczema only and 114 had rhinitis only. | — | [ ,
53.8 % Male samples |
— | Not reported | — | MAAS | — |
| PSS000318 | Setting II: Based on ICD codes and review of medical records from Partners HealthCare Biobank; controls = other non-matching arthritis diseases | Median = 8.0 years | [ ,
32.0 % Male samples |
— | European | — | PHB | — |
| PSS000319 | Setting III: Based on ICD codes and final diagnosis in medical records from Partners HealthCare Biobank; controls = other non-matching arthritis diseases | Median = 7.0 years | [ ,
32.0 % Male samples |
— | European | — | PHB | — |
| PSS000324 | Setting I: Based on ICD codes and expert opinion (ACR2010 criteria), in eMERGE network EMR database from Stanaway 2018; controls = other non-matching arthritis diseases | Median = 16.0 years | [ ,
43.0 % Male samples |
— | European, African unspecified, Asian unspecified, NR | Primarily European, African and Asian ancestry | eMERGE | — |
| PSS007808 | — | — | 2,406 individuals | — | African American or Afro-Caribbean | Carribean | UKB | — |
| PSS009362 | — | — | 19,352 individuals | — | European | UK (+ Ireland) | UKB | — |
| PSS009939 | — | — | 39,444 individuals | — | European (Finnish) |
— | FinnGen | — |
| PSS013177 | 477,J30 | — | [ ,
45.95 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013178 | 477,J30 | — | [ ,
45.95 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013179 | 477,J30 | — | [ ,
45.95 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013180 | 477,J30 | — | [ ,
45.95 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS013181 | 477,J30 | — | [ ,
45.95 % Male samples |
— | East Asian (Han Chinese) |
— | TPMI | — |
| PSS001027 | Cases were individuals with systemic lupus erythematosus (SLE). All cases were carefully recruited regarding the criteria from the American College of Rheumatology (ACR). Controls included healthy individuals and individuals who had unrelated diseases including: breast cancer, periodontitis, tuberculosis, drug-induced liver injury, epileptic encephalopathy, dengue hemorrhagic fever, thalassemia, and cardiomyopathy. | — | [ ,
40.31 % Male samples |
— | South East Asian (Thai) |
— | NR | Cases were recruited from King Chulalongkorn Memorial Hospital and the Rheumatology clinic at Ramathbodi hospital. Control data was provided by the Department of Medical Science, Min- istry of Public Health, Thailand. |
| PSS008912 | — | — | 3,818 individuals | — | African unspecified | Nigeria (West Africa) | UKB | — |
| PSS001028 | Cases were children with asthma ever, at age 8 years. Cases were defined using an adjusted diagnosis of asthma ever at age 8 years based on (1) 1 or more attacks of wheeze in the last 12 months or (2) inhaled corticosteroids for respiratory or lung problems prescribed by a doctor in the last 12 months. A child who had at least 1 of these characteristics was categorized as having asthma. | — | [ ,
56.2 % Male samples |
— | European (Swedish) |
— | BAMSE | Possible sample overlap of up to 100% between this dataset and the datasets used to source variants for GRSw_TAGC. |
| PSS001029 | Cases were children with asthma ever, at age 8 years, in which asthma was defined by the following characteristics: 1 or more attacks of wheeze in the last 12 months, 1 or more events of shortness of breath (dyspnea) in the last 12 months, or inhaled corticosteroids for respiratory or lung problems prescribed by a doctor in the last 12 months. A child who had 1 or more of these characteristics was categorized as having asthma. | — | [ ,
51.1 % Male samples |
— | European | — | PIAMA | Possible sample overlap of up to 19% between this dataset and the datasets used to source variants for GRSw_TAGC. |
| PSS004956 | — | — | 170 individuals | — | African unspecified | — | UKB | — |
| PSS004957 | — | — | 106 individuals | — | East Asian | — | UKB | — |
| PSS004958 | — | — | 1,421 individuals | — | European | non-white British ancestry | UKB | — |
| PSS004959 | — | — | 187 individuals | — | South Asian | — | UKB | — |
| PSS004960 | — | — | 3,857 individuals | — | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS001034 | Cases were individuals with cutaneous lupus erythematosus. Cases were identified by extracting clinical diagnoses from the electronic health record using the 9th and 10th International Statistical Classification of Diseases and Related Health Problems (ICD) Clinical Modification (CM) codes that mapped to the phenotype and transformed these ICD9/ICD10 codes into phecodes, which aggregate one or more related ICD codes into distinct diseases or traits. For each phenotype, cases were defined as individuals with 2 or more instances of the specific phecode in the electronic health record. Phecodes for lupus related disorders (systemic and cutaneous) include: 695.4, 695.41, 696.42. | — | [
|
— | European | — | BioVU | — |
| PSS001035 | Cases were individuals with systemic lupus erythematosus. Cases were identified by extracting clinical diagnoses from the electronic health record using the 9th and 10th International Statistical Classification of Diseases and Related Health Problems (ICD) Clinical Modification (CM) codes that mapped to the phenotype and transformed these ICD9/ICD10 codes into phecodes, which aggregate one or more related ICD codes into distinct diseases or traits. For each phenotype, cases were defined as individuals with 2 or more instances of the specific phecode in the electronic health record. Phecodes for lupus related disorders (systemic and cutaneous) include: 695.4, 695.41, 696.42. | — | [
|
— | European | — | BioVU | — |
| PSS001036 | Cases were individuals with type 1 diabetes. Cases were identified by extracting clinical diagnoses from the electronic health record using the 9th and 10th International Statistical Classification of Diseases and Related Health Problems (ICD) Clinical Modification (CM) codes that mapped to the phenotype and transformed these ICD9/ICD10 codes into phecodes, which aggregate one or more related ICD codes into distinct diseases or traits. For each phenotype, cases were defined as individuals with 2 or more instances of the specific phecode in the electronic health record. Phecodes for type 1 diabetes include: 250.1. Of all the type 1 diabetes cases, 276 had renal manifestations, 240 had ophthalmic manifestations and 475 had neurological manifestations | — | [
|
— | European | — | BioVU | — |
| PSS001037 | Cases were individuals with erythematosus conditions. Cases were identified by extracting clinical diagnoses from the electronic health record using the 9th and 10th International Statistical Classification of Diseases and Related Health Problems (ICD) Clinical Modification (CM) codes that mapped to the phenotype and transformed these ICD9/ICD10 codes into phecodes, which aggregate one or more related ICD codes into distinct diseases or traits. For each phenotype, cases were defined as individuals with 2 or more instances of the specific phecode in the electronic health record. Phecodes for lupus related disorders (systemic and cutaneous) include: 695.4, 695.41, 696.42. | — | [
|
— | European | — | BioVU | — |
| PSS001038 | Cases were individuals with lupus (localised and systemic). Cases were identified by extracting clinical diagnoses from the electronic health record using the 9th and 10th International Statistical Classification of Diseases and Related Health Problems (ICD) Clinical Modification (CM) codes that mapped to the phenotype and transformed these ICD9/ICD10 codes into phecodes, which aggregate one or more related ICD codes into distinct diseases or traits. For each phenotype, cases were defined as individuals with 2 or more instances of the specific phecode in the electronic health record. Phecodes for lupus related disorders (systemic and cutaneous) include: 695.4, 695.41, 696.42. | — | [
|
— | European | — | BioVU | — |
| PSS001039 | Cases were individuals with cutaneous lupus erythematosus. Cases were identified by extracting clinical diagnoses from the electronic health record using the 9th and 10th International Statistical Classification of Diseases and Related Health Problems (ICD) Clinical Modification (CM) codes that mapped to the phenotype and transformed these ICD9/ICD10 codes into phecodes, which aggregate one or more related ICD codes into distinct diseases or traits. For each phenotype, cases were defined as individuals with 2 or more instances of the specific phecode in the electronic health record. Phecodes for lupus related disorders (systemic and cutaneous) include: 695.4, 695.41, 696.42. | — | [
|
— | European | — | eMERGE | — |
| PSS001040 | Cases were individuals with systemic lupus erythematosus. Cases were identified by extracting clinical diagnoses from the electronic health record using the 9th and 10th International Statistical Classification of Diseases and Related Health Problems (ICD) Clinical Modification (CM) codes that mapped to the phenotype and transformed these ICD9/ICD10 codes into phecodes, which aggregate one or more related ICD codes into distinct diseases or traits. For each phenotype, cases were defined as individuals with 2 or more instances of the specific phecode in the electronic health record. Phecodes for lupus related disorders (systemic and cutaneous) include: 695.4, 695.41, 696.42. | — | [
|
— | European | — | eMERGE | — |
| PSS001041 | Cases were individuals with type 1 diabetes. Cases were identified by extracting clinical diagnoses from the electronic health record using the 9th and 10th International Statistical Classification of Diseases and Related Health Problems (ICD) Clinical Modification (CM) codes that mapped to the phenotype and transformed these ICD9/ICD10 codes into phecodes, which aggregate one or more related ICD codes into distinct diseases or traits. For each phenotype, cases were defined as individuals with 2 or more instances of the specific phecode in the electronic health record. Phecodes for type 1 diabetes include: 250.1. Of the type 1 diabetes cases 165 had renal manifestations, 230 had ophthalmic manifestations and 218 had neurological manifestations. | — | [
|
— | European | — | eMERGE | — |
| PSS001042 | Cases were individuals with erythematosus conditions. Cases were identified by extracting clinical diagnoses from the electronic health record using the 9th and 10th International Statistical Classification of Diseases and Related Health Problems (ICD) Clinical Modification (CM) codes that mapped to the phenotype and transformed these ICD9/ICD10 codes into phecodes, which aggregate one or more related ICD codes into distinct diseases or traits. For each phenotype, cases were defined as individuals with 2 or more instances of the specific phecode in the electronic health record. Phecodes for lupus related disorders (systemic and cutaneous) include: 695.4, 695.41, 696.42. | — | [
|
— | European | — | eMERGE | — |
| PSS001043 | Cases were individuals with lupus (localised and systemic). Cases were identified by extracting clinical diagnoses from the electronic health record using the 9th and 10th International Statistical Classification of Diseases and Related Health Problems (ICD) Clinical Modification (CM) codes that mapped to the phenotype and transformed these ICD9/ICD10 codes into phecodes, which aggregate one or more related ICD codes into distinct diseases or traits.For each phenotype, cases were defined as individuals with 2 or more instances of the specific phecode in the electronic health record.Phecodes for lupus related disorders (systemic and cutaneous) include: 695.4, 695.41, 696.42. | — | [
|
— | European | — | eMERGE | — |
| PSS011186 | — | — | [
|
— | European | — | BioVU | — |
| PSS011186 | — | — | [
|
— | African unspecified | — | BioVU | — |
| PSS011186 | — | — | [
|
— | Asian unspecified | — | BioVU | — |
| PSS011186 | — | — | [
|
— | Not reported | — | BioVU | — |
| PSS011187 | — | — | [
|
— | African unspecified | — | BioVU | — |
| PSS011188 | — | — | [
|
— | European | — | BioVU | — |
| PSS008464 | — | — | 1,172 individuals | — | Greater Middle Eastern (Middle Eastern, North African or Persian) | Iran (Middle East) | UKB | — |
| PSS003979 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS003980 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS003981 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS003982 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS003983 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS001055 | All individuals suffered from asthma and no other allergic diseases. All individuals were identified from a questionnaire. Asthmatic individuals were those with (i) both a report of “Asthma” in field 6152 of questionnaire (self-reported medical conditions, specifically the question “Has a doctor ever told you that you have had any of the following conditions?”) and a code for asthma in field 20002 (verbal interview), or alternatively, an ICD10 code for asthma in fields 41202 (Diagnoses–main ICD10) or 41204 (Diagnoses–secondary ICD10); and (ii) no report of COPD in fields 6152 or 20002, nor of other respiratory diseases in field 20002. | — | 22,029 individuals, 45.0 % Male samples |
Mean = 56.6 years Range = [38.0, 70.0] years |
European | — | UKB | Possible sample overlap of up to 100% between this dataset and the dataset used to source wGRS136_Allergy. |
| PSS001056 | All individuals suffered from eczema and no other allergic diseases. All individuals were identified from a questionnaire. The exact same approach (i.e. information from fields 20002, 41202 and 41204) was used to identify eczema cases. | — | 3,969 individuals, 43.0 % Male samples |
Mean = 55.4 years Range = [40.0, 70.0] years |
European | — | UKB | Possible sample overlap of up to 100% between this dataset and the dataset used to source wGRS136_Allergy. |
| PSS001057 | All individuals suffered from hay fever and no other allergic diseases. All individuals were identified from a questionnaire. To identify individuals who reported suffering specifically from hay fever, information reported in the verbal interview (field 20002) and ICD10 codes (fields 41202 and 41204) were considered, as described for asthma | — | 14,474 individuals, 49.0 % Male samples |
Mean = 55.1 years Range = [40.0, 70.0] years |
European | — | UKB | Possible sample overlap of up to 100% between this dataset and the dataset used to source wGRS136_Allergy. |
| PSS004511 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS004512 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS004513 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS004514 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS004515 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS011376 | — | Median = 12.0 years | 337,910 individuals, 45.6 % Male samples |
Mean = 57.1 years Sd = 8.0 years |
European | — | UKB | — |
| PSS008022 | — | — | 1,773 individuals | — | East Asian | China (East Asia) | UKB | — |
| PSS000960 | Cases were individuals with systemic lupus erythematosus. | — | [
|
— | European | — | NR | — |
| PSS000961 | Cases were individuals with systemic lupus erythematosus. | — | [
|
— | European | — | NR | — |
| PSS000962 | Cases were individuals with systemic lupus erythematosus. | — | [
|
— | European | — | NR | — |
| PSS000963 | Cases were individuals with systemic lupus erythematosus. | — | [
|
— | East Asian (Han Chinese) |
— | NR | — |
| PSS004069 | — | — | [
|
— | African unspecified | — | UKB | — |
| PSS004070 | — | — | [
|
— | East Asian | — | UKB | — |
| PSS004071 | — | — | [
|
— | European | non-white British ancestry | UKB | — |
| PSS004072 | — | — | [
|
— | South Asian | — | UKB | — |
| PSS004073 | — | — | [
|
— | European | white British ancestry | UKB | Testing cohort (heldout set) |
| PSS007661 | For the CHILD Cohort Study, atopic dermatitis (AD) was from physician diagnosis at the one year follow-up. AD severity was defined as mild if there is a single site or no more than 2 sites, minor symptoms (little itching/rubbing), minor crusting and papules, not excoriated or oozing, not needing frequent medical attention; was defined as moderate if symptoms are neither mild nor severe or; was defined as severe if there are multiple sites, with extensive crusting or papules or excoriations or oozing or lichenification, sleep loss, needing frequent medical attention, and is a major concern to parents. In the SLSJ Cohort, atopic dermatitis was self-reported and considered as positive if past or present occurrence was reported. For children, cross validation was done using questionnaires filled by their parents. Moreover, validation in medical records of these self-reported phenotypes were done for a subset of the SLSJ Cohort (n = 217), giving 89% concordance. | — | [ ,
42.0 % Male samples |
Mean = 9.0 years Range = [0.0, 87.0] years |
European, South East Asian, East Asian, South Asian, African American or Afro-Caribbean, Native American, Greater Middle Eastern (Middle Eastern, North African or Persian), Hispanic or Latin American, Not reported | — | CHILD, SLSJ | Also used to evaluate the PRS_atopicDermatitis for other diseases of the atopic march: food allergy, allergic asthma and rhinitis. Only unrelated individuals were selected for analyses. |
| PSS011006 | — | — | 1,655 individuals, 8.4 % Male samples |
Mean = 38.1 years Sd = 12.5 years |
East Asian (Korean) |
— | NR | — |
| PSS001091 | Cases were individuals who had been diagnosed by a phsyician with allergic symptoms. Allergic symptoms were diagnoised/defined using the International Classification of Primary Care (ICPC), allergic conjunctivitis (ICPC: F71), allergic rhinitis (ICPC: R97), or eczema/dermatitis (ICPC: S87, S88). | Median = 3.6 years IQR = [1.5, 6.7] years |
[ ,
49.2 % Male samples |
Median = 7.0 years IQR = [4.0, 9.0] years |
European (Dutch, NR) |
Dutch = 471, NR = 859 | WHISTLER | — |
| PSS010186 | Plaque psoriasis patients with at least one exposure to biologic therapy. Cases developed one or more paradoxical eczema adverse events during treatment with one of the following biologics: TNF-alpha inhibitors (adalimumab; etanercept; certolizumab; infliximab), IL-17 inhibitors (brodalumab; secukinumab; ixekizumab), IL-12/23 inhibitors (ustekinumab) and IL-23p19 inhibitors (guselkumab; risankizumab; tildrakizumab). Controls has no recorded eczema events during biologic therapy. Participants may have been exposed to more than one biologic. | — | [
|
— | European | — | BSTOP | — |
| PSS009136 | — | — | 4,025 individuals | — | European | Poland (NE Europe) | UKB | — |